{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T01:45:27Z","timestamp":1776217527794,"version":"3.50.1"},"reference-count":116,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,8,17]],"date-time":"2024-08-17T00:00:00Z","timestamp":1723852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,17]],"date-time":"2024-08-17T00:00:00Z","timestamp":1723852800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"USAID","award":["No. AID-OAA-A-16-00031"],"award-info":[{"award-number":["No. AID-OAA-A-16-00031"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Behav"],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Historically, pregnant and lactating populations (PLP) have been excluded or disenrolled from biomedical HIV prevention trials, despite being more likely to acquire HIV during pregnancy and the post-partum period. We conducted a meta-analysis of pregnancy events in biomedical HIV prevention trials in sub-Saharan Africa to support trialists moving toward more inclusive clinical and implementation studies. We searched peer-reviewed literature reporting pregnancy events and contraceptive requirements in HIV prevention trials between 2001 and 2022. We hypothesized four variables to explain variation: contraceptive requirements, study start year, study product, and sub-region. We fit a meta-analytic model to estimate individual effect sizes and sampling variances, then conducted sub-group analyses to assess moderating effects.\u00a0We identified 38 references for inclusion, across which the proportion of pregnancy events was 8% (95% confidence interval [CI]: 6\u201310%) with high heterogeneity (I<jats:sup>2<\/jats:sup>\u2009=\u200999%). Studies not requiring contraceptives (21%, 95%CI: 7\u201348%) reported a significantly higher proportion of pregnancy events than studies requiring two methods (5%, 95%CI: 2\u201310%). Studies launched between 2001 and 2007 (11%, 95%CI: 8\u201316%), microbicide gel trials (12%, 95%CI: 8\u201318%), and studies conducted in Western Africa (28%, 95%CI: 13\u201351%) reported higher proportions of pregnancy events than reference groups. Together, these variables have a moderating effect on pregnancy events (p\u2009&lt;\u20090.0001), explaining 63% of heterogeneity in trials. Results describe how, over time, more stringent contraceptive requirements reduced pregnancy events, which ensured necessary statistical power but limited reproductive choice by participants. With the move toward continuing PLP on experimental products, trialists can utilize estimated pregnancy events reported here to inform strategies that accommodate participants\u2019 changing fertility preferences.<\/jats:p>","DOI":"10.1007\/s10461-024-04459-z","type":"journal-article","created":{"date-parts":[[2024,8,17]],"date-time":"2024-08-17T06:32:16Z","timestamp":1723876336000},"page":"3850-3872","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Meta-analysis of Pregnancy Events in Biomedical HIV Prevention Trials in Sub-Saharan Africa: Implications for Gender Transformative Trials"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4758-7390","authenticated-orcid":false,"given":"Lara","family":"Lorenzetti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9887-7729","authenticated-orcid":false,"given":"Nhi","family":"Dinh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5234-8178","authenticated-orcid":false,"given":"Cason","family":"Whitcomb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0763-1978","authenticated-orcid":false,"given":"Andres","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manju","family":"Chatani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Breanne","family":"Lievense","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6058-5237","authenticated-orcid":false,"given":"Definate","family":"Nhamo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6608-0248","authenticated-orcid":false,"given":"Catherine","family":"Slack","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalie","family":"Eley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2436-4741","authenticated-orcid":false,"given":"Kathleen","family":"MacQueen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,17]]},"reference":[{"issue":"12","key":"4459_CR1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0260555","volume":"16","author":"G Ayala","year":"2021","unstructured":"Ayala G, Sprague L, van der Merwe LL, Thomas RM, Chang J, Arreola S, et al. Peer- and community-led responses to HIV: a scoping review. PLoS ONE. 2021;16(12): e0260555.","journal-title":"PLoS ONE"},{"issue":"6","key":"4459_CR2","doi-asserted-by":"publisher","first-page":"396","DOI":"10.2174\/157016211798038588","volume":"9","author":"D Barr","year":"2011","unstructured":"Barr D, Amon JJ, Clayton M. Articulating a rights-based approach to HIV treatment and prevention interventions. Curr HIV Res. 2011;9(6):396\u2013404.","journal-title":"Curr HIV Res"},{"issue":"10","key":"4459_CR3","doi-asserted-by":"publisher","first-page":"e78208e-e","DOI":"10.1371\/journal.pone.0078208","volume":"8","author":"SA Lippman","year":"2013","unstructured":"Lippman SA, Maman S, MacPhail C, Twine R, Peacock D, Kahn K, et al. Conceptualizing community mobilization for HIV prevention: implications for HIV prevention programming in the African context. PLoS ONE. 2013;8(10):e78208e-e.","journal-title":"PLoS ONE"},{"key":"4459_CR4","unstructured":"African Commission on Human Rights. HIV, the law, and Human Rights in the African Human Rights System: Key Challenges and Opportunities for Rights-Based Responses. UNAIDS; 2018."},{"issue":"9","key":"4459_CR5","doi-asserted-by":"publisher","first-page":"2845","DOI":"10.1007\/s10461-013-0565-2","volume":"17","author":"SL Dworkin","year":"2013","unstructured":"Dworkin SL, Treves-Kagan S, Lippman SA. Gender-transformative interventions to reduce HIV risks and violence with heterosexually-active men: a review of the global evidence. AIDS Behav. 2013;17(9):2845\u201363.","journal-title":"AIDS Behav"},{"issue":"Suppl 1","key":"4459_CR6","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1080\/10810730.2014.918216","volume":"19","author":"JM Kraft","year":"2014","unstructured":"Kraft JM, Wilkins KG, Morales GJ, Widyono M, Middlestadt SE. An evidence review of gender-integrated interventions in reproductive and maternal-child health. J Health Commun. 2014;19(Suppl 1):122\u201341.","journal-title":"J Health Commun"},{"key":"4459_CR7","unstructured":"UNAIDS. Political declaration on HIV and AIDS: ending inequalities and getting back on track to end AIDS by 2030. UNAIDS Geneva; 2021."},{"issue":"4","key":"4459_CR8","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1097\/AOG.0b013e31822be512","volume":"118","author":"S Sibeko","year":"2011","unstructured":"Sibeko S, Baxter C, Yende N, Karim QA, Karim SSA. Contraceptive choices, pregnancy rates, and outcomes in a microbicide trial. Obstet Gynecol. 2011;118(4):895\u2013904.","journal-title":"Obstet Gynecol"},{"issue":"4","key":"4459_CR9","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.bpobgyn.2012.01.005","volume":"26","author":"S Sibeko","year":"2012","unstructured":"Sibeko S, Cohen GM, Moodley J. Contraception and pregnancy in microbicide trials. Best Pract Res Clin Obstet Gynaecol. 2012;26(4):473\u201386.","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"4459_CR10","doi-asserted-by":"crossref","unstructured":"Baylis F, Ballantyne A. Clinical research involving pregnant women: Springer; 2017.","DOI":"10.1007\/978-3-319-26512-4"},{"issue":"2","key":"4459_CR11","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1097\/QAI.0000000000000842","volume":"71","author":"MJ Curno","year":"2016","unstructured":"Curno MJ, Rossi S, Hodges-Mameletzis I, Johnston R, Price MA, Heidari S. A systematic review of the inclusion (or exclusion) of women in HIV research: from clinical studies of antiretrovirals and vaccines to cure strategies. J Acquir Immune Defic Syndr. 2016;71(2):181\u20138.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"6","key":"4459_CR12","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1071\/SH18067","volume":"15","author":"N Davies","year":"2018","unstructured":"Davies N, Heffron R. Global and national guidance for the use of pre-exposure prophylaxis during peri-conception, pregnancy and breastfeeding. Sex Health. 2018;15(6):501\u201312.","journal-title":"Sex Health"},{"issue":"1","key":"4459_CR13","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s12981-020-00271-6","volume":"17","author":"K Sullivan","year":"2020","unstructured":"Sullivan K, Mtande T, Jaffe E, Rosenberg N, Zimba C, Hoffman I, et al. Views among Malawian women about joining HIV prevention clinical trials when pregnant. AIDS Res Ther. 2020;17(1):27.","journal-title":"AIDS Res Ther"},{"issue":"1","key":"4459_CR14","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1089\/jwh.2017.6857","volume":"28","author":"MN Wickremsinhe","year":"2019","unstructured":"Wickremsinhe MN, Little MO, Carter AS, Sullivan KA, Lyerly AD. Beyond \u201cvessels and vectors\u201d: a global review of registered hiv-related clinical trials with pregnant women. J Womens Health (Larchmt). 2019;28(1):93\u20139.","journal-title":"J Womens Health (Larchmt)"},{"issue":"15","key":"4459_CR15","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1097\/QAD.0b013e32834a9338","volume":"25","author":"NR Mugo","year":"2011","unstructured":"Mugo NR, Heffron R, Donnell D, Wald A, Were EO, Rees H, et al. Increased risk of HIV-1 transmission in pregnancy: a prospective study among African HIV-1-serodiscordant couples. AIDS (London, England). 2011;25(15):1887\u201395.","journal-title":"AIDS (London, England)"},{"issue":"1","key":"4459_CR16","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1093\/infdis\/jiy113","volume":"218","author":"KA Thomson","year":"2018","unstructured":"Thomson KA, Hughes J, Baeten JM, John-Stewart G, Celum C, Cohen CR, et al. Increased risk of HIV acquisition among women throughout pregnancy and during the postpartum period: a prospective per-coital-act analysis among women with HIV-infected partners. J Infect Dis. 2018;218(1):16\u201325.","journal-title":"J Infect Dis"},{"issue":"7","key":"4459_CR17","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1093\/cid\/ciz121","volume":"69","author":"A Colbers","year":"2019","unstructured":"Colbers A, Mirochnick M, Schalkwijk S, Penazzato M, Townsend C, Burger D. Importance of prospective studies in pregnant and breastfeeding women living with human immunodeficiency virus. Clin Infectious Dis\u202f: Official Publ Infectious Dis Soc Am. 2019;69(7):1254\u20138.","journal-title":"Clin Infectious Dis : Official Publ Infectious Dis Soc Am"},{"issue":"5996","key":"4459_CR18","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1126\/science.1193748","volume":"329","author":"Q Abdool Karim","year":"2010","unstructured":"Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329(5996):1168\u201374.","journal-title":"Science"},{"issue":"5","key":"4459_CR19","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1056\/NEJMoa1108524","volume":"367","author":"JM Baeten","year":"2012","unstructured":"Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399\u2013410.","journal-title":"N Engl J Med"},{"issue":"6","key":"4459_CR20","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1056\/NEJMoa1402269","volume":"372","author":"JM Marrazzo","year":"2015","unstructured":"Marrazzo JM, Ramjee G, Richardson BA, Gomez K, Mgodi N, Nair G, et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2015;372(6):509\u201318.","journal-title":"N Engl J Med"},{"issue":"10","key":"4459_CR21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0077014","volume":"8","author":"A Musekiwa","year":"2013","unstructured":"Musekiwa A, Muchiri E, Manda SO, Mwambi HG. Pregnancy incidence and risk factors among women participating in vaginal microbicide trials for HIV prevention: systematic review and meta-analysis. PLoS ONE. 2013;8(10): e77014.","journal-title":"PLoS ONE"},{"issue":"1","key":"4459_CR22","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1136\/jfprhc-2014-101100","volume":"42","author":"J Moodley","year":"2016","unstructured":"Moodley J, Naidoo S, Wand H, Ramjee G. Contraception use and impact on pregnancy prevention in women participating in an HIV prevention trial in South Africa. J Fam Plann Reprod Health Care. 2016;42(1):5\u201311.","journal-title":"J Fam Plann Reprod Health Care"},{"issue":"10195","key":"4459_CR23","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0140-6736(19)31288-7","volume":"394","author":"Evidence for Contraceptive Options and HIV Outcomes (ECHO)","year":"2019","unstructured":"Evidence for Contraceptive Options and HIV Outcomes (ECHO). Trial Consortium HIV incidence among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: a randomised, multicentre, open-label trial. Lancet. 2019;394(10195):303\u201313.","journal-title":"Lancet"},{"issue":"5","key":"4459_CR24","doi-asserted-by":"publisher","first-page":"e0216332-e","DOI":"10.1371\/journal.pone.0216332","volume":"14","author":"KA Sullivan","year":"2019","unstructured":"Sullivan KA, Little MO, Rosenberg NE, Zimba C, Jaffe E, Gilbert S, et al. Women\u2019s views about contraception requirements for biomedical research participation. PLoS ONE. 2019;14(5):e0216332-e.","journal-title":"PLoS ONE"},{"key":"4459_CR25","unstructured":"AVAC. Including Pregnant and Lactating Populations in HIV Prevention Research 2023 [Available from: https:\/\/www.avac.org\/including-plp."},{"issue":"7","key":"4459_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000100","volume":"6","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6(7): e1000100.","journal-title":"PLoS Med"},{"issue":"3","key":"4459_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v036.i03","volume":"36","author":"W Viechtbauer","year":"2010","unstructured":"Viechtbauer W. Conducting Meta-Analyses in R with the metafor Package. J Stat Softw. 2010;36(3):1\u201348.","journal-title":"J Stat Softw"},{"issue":"4","key":"4459_CR28","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","volume":"22","author":"S Balduzzi","year":"2019","unstructured":"Balduzzi S, R\u00fccker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Health. 2019;22(4):153\u201360.","journal-title":"Evid Based Ment Health"},{"key":"4459_CR29","unstructured":"Wang N. How to Conduct a Meta-Analysis of Proportions in R: A Comprehensive Tutorial2018."},{"key":"4459_CR30","volume-title":"The analysis of variance: fixed, random and mixed models","author":"H Sahai","year":"2012","unstructured":"Sahai H, Ageel M. The analysis of variance: fixed, random and mixed models. Boston: Birkhauser; 2012."},{"key":"4459_CR31","volume-title":"Practical meta-analysis","author":"M Lipsey","year":"2001","unstructured":"Lipsey M, Wilson D. Practical meta-analysis. New York: Sage Publications; 2001."},{"key":"4459_CR32","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/B978-0-08-057065-5.50014-2","volume-title":"Statistical methods for meta-analysis","author":"LV Hedges","year":"1985","unstructured":"Hedges LV, Olkin I. Chapter 9: Random effects models for effect sizes. In: Statistical methods for meta-analysis. Academic Press, Cambridge; 1985. p. 189\u2013203."},{"issue":"7414","key":"4459_CR33","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ (Clinical research ed). 2003;327(7414):557\u201360.","journal-title":"BMJ (Clinical research ed)"},{"key":"4459_CR34","doi-asserted-by":"publisher","DOI":"10.4324\/9780203852279","volume-title":"Multilevel analysis: techniques and applications","author":"J Hox","year":"2010","unstructured":"Hox J. Multilevel analysis: techniques and applications. 2nd ed. London: Routledge\/Taylor & Francis Group; 2010.","edition":"2"},{"issue":"1","key":"4459_CR35","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13643-018-0925-0","volume":"8","author":"CE Kennedy","year":"2019","unstructured":"Kennedy CE, Fonner VA, Armstrong KA, Denison JA, Yeh PT, O\u2019Reilly KR, et al. The Evidence Project risk of bias tool: assessing study rigor for both randomized and non-randomized intervention studies. Syst Rev. 2019;8(1):3.","journal-title":"Syst Rev"},{"issue":"3","key":"4459_CR36","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.contraception.2009.10.011","volume":"81","author":"CE von Mollendorf","year":"2010","unstructured":"von Mollendorf CE, Van Damme L, Moyes JA, Rees VH, Callahan MM, Mauck CK, et al. Results of a safety and feasibility study of the diaphragm used with ACIDFORM Gel or K-Y Jelly. Contraception. 2010;81(3):232\u20139.","journal-title":"Contraception"},{"issue":"3","key":"4459_CR37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0056400","volume":"8","author":"LT Matthews","year":"2013","unstructured":"Matthews LT, Sibeko S, Mansoor LE, Yende-Zuma N, Bangsberg DR, Karim QA. Women with pregnancies had lower adherence to 1% tenofovir vaginal gel as HIV preexposure prophylaxis in CAPRISA 004, a phase IIB randomized-controlled trial. PLoS ONE. 2013;8(3): e56400.","journal-title":"PLoS ONE"},{"issue":"6","key":"4459_CR38","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.contraception.2010.04.019","volume":"82","author":"Carraguard Phase IISAST","year":"2010","unstructured":"Carraguard Phase IISAST. Expanded safety and acceptability of the candidate vaginal microbicide Carraguard(R) in South Africa. Contraception. 2010;82(6):563\u201371.","journal-title":"Contraception"},{"issue":"9654","key":"4459_CR39","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1016\/S0140-6736(08)61842-5","volume":"372","author":"S Skoler-Karpoff","year":"2008","unstructured":"Skoler-Karpoff S, Ramjee G, Ahmed K, Altini L, Gheret Plagianos M, Friedland B, et al. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372(9654):1977\u201387.","journal-title":"Lancet"},{"key":"4459_CR40","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12981-016-0098-7","volume":"13","author":"Z Gaffoor","year":"2016","unstructured":"Gaffoor Z, Wand H, Street RA, Abbai N, Ramjee G. Predictors of perceived male partner concurrency among women at risk for HIV and STI acquisition in Durban. South Africa AIDS Res Ther. 2016;13:14.","journal-title":"South Africa AIDS Res Ther"},{"issue":"5","key":"4459_CR41","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.contraception.2007.07.004","volume":"76","author":"A van der Straten","year":"2007","unstructured":"van der Straten A, Napierala S, Cheng H, Mauck C, Depineres T, Dhlakama P, et al. A randomized controlled safety trial of the diaphragm and cellulose sulfate microbicide gel in sexually active women in Zimbabwe. Contraception. 2007;76(5):389\u201399.","journal-title":"Contraception"},{"issue":"11","key":"4459_CR42","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0003784","volume":"3","author":"V Halpern","year":"2008","unstructured":"Halpern V, Ogunsola F, Obunge O, Wang CH, Onyejepu N, Oduyebo O, et al. Effectiveness of cellulose sulfate vaginal gel for the prevention of HIV infection: results of a Phase III trial in Nigeria. PLoS ONE. 2008;3(11): e3784.","journal-title":"PLoS ONE"},{"issue":"2","key":"4459_CR43","doi-asserted-by":"publisher","first-page":"e77","DOI":"10.1016\/S2352-3018(20)30300-3","volume":"8","author":"A Nel","year":"2021","unstructured":"Nel A, van Niekerk N, Van Baelen B, Malherbe M, Mans W, Carter A, et al. Safety, adherence, and HIV-1 seroconversion among women using the dapivirine vaginal ring (DREAM): an open-label, extension study. Lancet HIV. 2021;8(2):e77\u201386.","journal-title":"Lancet HIV"},{"issue":"18","key":"4459_CR44","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1097\/01.aids.0000194129.05264.55","volume":"19","author":"JM Bakobaki","year":"2005","unstructured":"Bakobaki JM, Lacey CJ, Bukenya MI, Nunn AJ, McCormack S, Byaruhanga RN, et al. A randomized controlled safety and acceptability trial of dextrin sulphate vaginal microbicide gel in sexually active women in Uganda. AIDS (London, England). 2005;19(18):2149\u201356.","journal-title":"AIDS (London, England)"},{"issue":"11","key":"4459_CR45","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1016\/S1473-3099(18)30428-6","volume":"18","author":"S Delany-Moretlwe","year":"2018","unstructured":"Delany-Moretlwe S, Lombard C, Baron D, Bekker LG, Nkala B, Ahmed K, et al. Tenofovir 1% vaginal gel for prevention of HIV-1 infection in women in South Africa (FACTS-001): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Infect Dis. 2018;18(11):1241\u201350.","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"4459_CR46","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1097\/QAI.0000000000002785","volume":"88","author":"H Rees","year":"2021","unstructured":"Rees H, Chersich MF, Munthali RJ, Brumskine W, Palanee-Phillips T, Nkala B, et al. HIV Incidence Among Pregnant and Nonpregnant Women in the FACTS-001 Trial: Implications for HIV Prevention, Especially PrEP Use. J Acquir Immune Defic Syndr. 2021;88(4):376\u201383.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"5","key":"4459_CR47","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1202614","volume":"367","author":"L Van Damme","year":"2012","unstructured":"Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367(5):411\u201322.","journal-title":"N Engl J Med"},{"issue":"3","key":"4459_CR48","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.contraception.2014.10.008","volume":"91","author":"CS Todd","year":"2015","unstructured":"Todd CS, Deese J, Wang M, Hubacher D, Steiner MJ, Otunga S, et al. Sino-implant (II)(R) continuation and effect of concomitant tenofovir disoproxil fumarate-emtricitabine use on plasma levonorgestrel concentrations among women in Bondo. Kenya Contraception. 2015;91(3):248\u201352.","journal-title":"Kenya Contraception"},{"issue":"1","key":"4459_CR49","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.contraception.2016.03.003","volume":"94","author":"K Nanda","year":"2016","unstructured":"Nanda K, Callahan R, Taylor D, Wang M, Agot K, Jenkins D, et al. Medroxyprogesterone acetate levels among Kenyan women using depot medroxyprogesterone acetate in the FEM-PrEP trial. Contraception. 2016;94(1):40\u20137.","journal-title":"Contraception"},{"issue":"46","key":"4459_CR50","doi-asserted-by":"publisher","first-page":"8417","DOI":"10.1016\/j.vaccine.2011.08.001","volume":"29","author":"M Bakari","year":"2011","unstructured":"Bakari M, Aboud S, Nilsson C, Francis J, Buma D, Moshiro C, et al. Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania. Vaccine. 2011;29(46):8417\u201328.","journal-title":"Vaccine"},{"issue":"1","key":"4459_CR51","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.contraception.2015.10.010","volume":"93","author":"JE Balkus","year":"2016","unstructured":"Balkus JE, Brown ER, Hillier SL, Coletti A, Ramjee G, Mgodi N, et al. Oral and injectable contraceptive use and HIV acquisition risk among women in four African countries: a secondary analysis of data from a microbicide trial. Contraception. 2016;93(1):25\u201331.","journal-title":"Contraception"},{"issue":"10337","key":"4459_CR52","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1016\/S0140-6736(22)00538-4","volume":"399","author":"S Delany-Moretlwe","year":"2022","unstructured":"Delany-Moretlwe S, Hughes JP, Bock P, Ouma SG, Hunidzarira P, Kalonji D, et al. Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial. Lancet. 2022;399(10337):1779\u201389.","journal-title":"Lancet"},{"issue":"9","key":"4459_CR53","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0161753","volume":"11","author":"G Churchyard","year":"2016","unstructured":"Churchyard G, Mlisana K, Karuna S, Williamson AL, Williamson C, Morris L, et al. Sequential Immunization with gp140 Boosts Immune Responses Primed by Modified Vaccinia Ankara or DNA in HIV-Uninfected South African Participants. PLoS ONE. 2016;11(9): e0161753.","journal-title":"PLoS ONE"},{"issue":"510","key":"4459_CR54","doi-asserted-by":"publisher","first-page":"eaax1880","DOI":"10.1126\/scitranslmed.aax1880","volume":"11","author":"GE Gray","year":"2019","unstructured":"Gray GE, Huang Y, Grunenberg N, Laher F, Roux S, Andersen-Nissen E, et al. Immune correlates of the Thai RV144 HIV vaccine regimen in South Africa. Sci Transl Med. 2019;11(510):eaax1880.","journal-title":"Sci Transl Med."},{"issue":"2","key":"4459_CR55","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003038","volume":"17","author":"F Laher","year":"2020","unstructured":"Laher F, Moodie Z, Cohen KW, Grunenberg N, Bekker LG, Allen M, et al. Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: a randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120\/MF59 vaccines. PLoS Med. 2020;17(2): e1003038.","journal-title":"PLoS Med"},{"issue":"7","key":"4459_CR56","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/S1473-3099(11)70098-6","volume":"11","author":"GE Gray","year":"2011","unstructured":"Gray GE, Allen M, Moodie Z, Churchyard G, Bekker LG, Nchabeleng M, et al. Safety and efficacy of the HVTN 503\/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study. Lancet Infect Dis. 2011;11(7):507\u201315.","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"4459_CR57","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0031387","volume":"7","author":"MH Latka","year":"2012","unstructured":"Latka MH, Fielding K, Gray GE, Bekker LG, Nchabeleng M, Mlisana K, et al. Pregnancy incidence and correlates during the HVTN 503 Phambili HIV vaccine trial conducted among South African women. PLoS ONE. 2012;7(4): e31387.","journal-title":"PLoS ONE"},{"issue":"1","key":"4459_CR58","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0241708","volume":"16","author":"R Mpofu","year":"2021","unstructured":"Mpofu R, Otwombe K, Mlisana K, Nchabeleng M, Allen M, Kublin J, et al. Benign ethnic neutropenia in a South African population, and its association with HIV acquisition and adverse event reporting in an HIV vaccine clinical trial. PLoS ONE. 2021;16(1): e0241708.","journal-title":"PLoS ONE"},{"issue":"12","key":"4459_CR59","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2031499","volume":"384","author":"GE Gray","year":"2021","unstructured":"Gray GE, Bekker LG, Laher F, Malahleha M, Allen M, Moodie Z, et al. Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120-MF59 in Adults. N Engl J Med. 2021;384(12):1089\u2013100.","journal-title":"N Engl J Med"},{"issue":"1","key":"4459_CR60","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1097\/QAI.0000000000002649","volume":"87","author":"NM Mgodi","year":"2021","unstructured":"Mgodi NM, Takuva S, Edupuganti S, Karuna S, Andrew P, Lazarus E, et al. A phase 2b study to evaluate the safety and efficacy of VRC01 broadly neutralizing monoclonal antibody in reducing acquisition of HIV-1 infection in women in Sub-Saharan Africa: Baseline Findings. J Acquir Immune Defic Syndr. 2021;87(1):680\u20137.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"9749","key":"4459_CR61","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/S0140-6736(10)61086-0","volume":"376","author":"S McCormack","year":"2010","unstructured":"McCormack S, Ramjee G, Kamali A, Rees H, Crook AM, Gafos M, et al. PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial. Lancet. 2010;376(9749):1329\u201337.","journal-title":"Lancet"},{"key":"4459_CR62","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1745-6215-14-33","volume":"14","author":"A Abaasa","year":"2013","unstructured":"Abaasa A, Crook A, Gafos M, Anywaine Z, Levin J, Wandiembe S, et al. Long-term consistent use of a vaginal microbicide gel among HIV-1 sero-discordant couples in a phase III clinical trial (MDP 301) in rural south-west Uganda. Trials. 2013;14:33.","journal-title":"Trials"},{"issue":"8","key":"4459_CR63","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1093\/humrep\/deu113","volume":"29","author":"AM Crook","year":"2014","unstructured":"Crook AM, Ford D, Gafos M, Hayes R, Kamali A, Kapiga S, et al. Injectable and oral contraceptives and risk of HIV acquisition in women: an analysis of data from the MDP301 trial. Hum Reprod. 2014;29(8):1810\u20137.","journal-title":"Hum Reprod"},{"issue":"9583","key":"4459_CR64","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S0140-6736(07)60950-7","volume":"370","author":"NS Padian","year":"2007","unstructured":"Padian NS, van der Straten A, Ramjee G, Chipato T, de Bruyn G, Blanchard K, et al. Diaphragm and lubricant gel for prevention of HIV acquisition in southern African women: a randomised controlled trial. Lancet. 2007;370(9583):251\u201361.","journal-title":"Lancet"},{"issue":"6","key":"4459_CR65","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.contraception.2010.10.018","volume":"83","author":"K Blanchard","year":"2011","unstructured":"Blanchard K, Bostrom A, Montgomery E, van der Straten A, Lince N, de Bruyn G, et al. Contraception use and effectiveness among women in a trial of the diaphragm for HIV prevention. Contraception. 2011;83(6):556\u201363.","journal-title":"Contraception"},{"issue":"4","key":"4459_CR66","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1136\/jfprhc-2011-0109","volume":"37","author":"K Blanchard","year":"2011","unstructured":"Blanchard K, Holt K, Bostrom A, van der Straten A, Ramjee G, de Bruyn G, et al. Impact of learning HIV status on contraceptive use in the MIRA trial. J Fam Plann Reprod Health Care. 2011;37(4):204\u20138.","journal-title":"J Fam Plann Reprod Health Care"},{"issue":"6","key":"4459_CR67","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1097\/QAD.0b013e32835da401","volume":"27","author":"SI McCoy","year":"2013","unstructured":"McCoy SI, Zheng W, Montgomery ET, Blanchard K, van der Straten A, de Bruyn G, et al. Oral and injectable contraception use and risk of HIV acquisition among women in sub-Saharan Africa. AIDS (London, England). 2013;27(6):1001\u20139.","journal-title":"AIDS (London, England)"},{"issue":"6","key":"4459_CR68","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1089\/jwh.2016.5958","volume":"26","author":"CA Akello","year":"2017","unstructured":"Akello CA, Bunge KE, Nakabiito C, Mirembe BG, Fowler MG, Mishra A, et al. Contraceptive use and pregnancy incidence among women participating in an HIV prevention trial. J Womens Health (Larchmt). 2017;26(6):670\u20136.","journal-title":"J Womens Health (Larchmt)"},{"issue":"5","key":"4459_CR69","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1097\/QAI.0000000000001861","volume":"79","author":"B Makanani","year":"2018","unstructured":"Makanani B, Balkus JE, Jiao Y, Noguchi LM, Palanee-Phillips T, Mbilizi Y, et al. Pregnancy and infant outcomes among women using the dapivirine vaginal ring in early pregnancy. J Acquir Immune Defic Syndr. 2018;79(5):566\u201372.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"2","key":"4459_CR70","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1097\/QAI.0000000000001455","volume":"76","author":"JE Balkus","year":"2017","unstructured":"Balkus JE, Palanee-Phillips T, Reddy K, Siva S, Harkoo I, Nakabiito C, et al. Brief report: dapivirine vaginal ring use does not diminish the effectiveness of hormonal contraception. J Acquir Immune Defic Syndr. 2017;76(2):e47\u201351.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"4","key":"4459_CR71","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1001\/jama.2014.8735","volume":"312","author":"NR Mugo","year":"2014","unstructured":"Mugo NR, Hong T, Celum C, Donnell D, Bukusi EA, John-Stewart G, et al. Pregnancy incidence and outcomes among women receiving preexposure prophylaxis for HIV prevention: a randomized clinical trial. JAMA. 2014;312(4):362\u201371.","journal-title":"JAMA"},{"issue":"12","key":"4459_CR72","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/S1473-3099(13)70226-3","volume":"13","author":"KK Mugwanya","year":"2013","unstructured":"Mugwanya KK, Donnell D, Celum C, Thomas KK, Ndase P, Mugo N, et al. Sexual behaviour of heterosexual men and women receiving antiretroviral pre-exposure prophylaxis for HIV prevention: a longitudinal analysis. Lancet Infect Dis. 2013;13(12):1021\u20138.","journal-title":"Lancet Infect Dis"},{"issue":"12","key":"4459_CR73","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1097\/QAD.0000000000000290","volume":"28","author":"PM Murnane","year":"2014","unstructured":"Murnane PM, Heffron R, Ronald A, Bukusi EA, Donnell D, Mugo NR, et al. Pre-exposure prophylaxis for HIV-1 prevention does not diminish the pregnancy prevention effectiveness of hormonal contraception. AIDS (London, England). 2014;28(12):1825\u201330.","journal-title":"AIDS (London, England)"},{"issue":"9","key":"4459_CR74","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0074314","volume":"8","author":"FM Kibengo","year":"2013","unstructured":"Kibengo FM, Ruzagira E, Katende D, Bwanika AN, Bahemuka U, Haberer JE, et al. Safety, adherence and acceptability of intermittent tenofovir\/emtricitabine as HIV pre-exposure prophylaxis (PrEP) among HIV-uninfected Ugandan volunteers living in HIV-serodiscordant relationships: a randomized, clinical trial. PLoS ONE. 2013;8(9): e74314.","journal-title":"PLoS ONE"},{"issue":"8","key":"4459_CR75","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1089\/aid.2009.0242","volume":"26","author":"E Vardas","year":"2010","unstructured":"Vardas E, Kaleebu P, Bekker LG, Hoosen A, Chomba E, Johnson PR, et al. A phase 2 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 vaccine based on adeno-associated virus. AIDS Res Hum Retroviruses. 2010;26(8):933\u201342.","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"4","key":"4459_CR76","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0005164","volume":"4","author":"H Kibuuka","year":"2009","unstructured":"Kibuuka H, Guwatudde D, Kimutai R, Maganga L, Maboko L, Watyema C, et al. Contraceptive use in women enrolled into preventive HIV vaccine trials: experience from a phase I\/II trial in East Africa. PLoS ONE. 2009;4(4): e5164.","journal-title":"PLoS ONE"},{"issue":"4","key":"4459_CR77","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1086\/650299","volume":"201","author":"H Kibuuka","year":"2010","unstructured":"Kibuuka H, Kimutai R, Maboko L, Sawe F, Schunk MS, Kroidl A, et al. A phase 1\/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-Uninfected East Africans (RV 172). J Infect Dis. 2010;201(4):600\u20137.","journal-title":"J Infect Dis"},{"issue":"12","key":"4459_CR78","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0001312","volume":"2","author":"L Peterson","year":"2007","unstructured":"Peterson L, Nanda K, Opoku BK, Ampofo WK, Owusu-Amoako M, Boakye AY, et al. SAVVY (C31G) gel for prevention of HIV infection in women: a Phase 3, double-blind, randomized, placebo-controlled trial in Ghana. PLoS ONE. 2007;2(12): e1312.","journal-title":"PLoS ONE"},{"issue":"1","key":"4459_CR79","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0001474","volume":"3","author":"PJ Feldblum","year":"2008","unstructured":"Feldblum PJ, Adeiga A, Bakare R, Wevill S, Lendvay A, Obadaki F, et al. SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomized controlled trial in Nigeria. PLoS ONE. 2008;3(1): e1474.","journal-title":"PLoS ONE"},{"issue":"5","key":"4459_CR80","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0155702","volume":"11","author":"A Joachim","year":"2016","unstructured":"Joachim A, Bauer A, Joseph S, Geldmacher C, Munseri PJ, Aboud S, et al. Boosting with subtype C CN54rgp140 protein adjuvanted with glucopyranosyl lipid adjuvant after priming with HIV-DNA and HIV-MVA Is safe and enhances immune responses: a phase I trial. PLoS ONE. 2016;11(5): e0155702.","journal-title":"PLoS ONE"},{"issue":"4","key":"4459_CR81","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0119629","volume":"10","author":"PJ Munseri","year":"2015","unstructured":"Munseri PJ, Kroidl A, Nilsson C, Joachim A, Geldmacher C, Mann P, et al. Priming with a simplified intradermal HIV-1 DNA vaccine regimen followed by boosting with recombinant HIV-1 MVA vaccine is safe and immunogenic: a phase IIa randomized clinical trial. PLoS ONE. 2015;10(4): e0119629.","journal-title":"PLoS ONE"},{"issue":"11","key":"4459_CR82","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0206838","volume":"13","author":"EO Viegas","year":"2018","unstructured":"Viegas EO, Kroidl A, Munseri PJ, Missanga M, Nilsson C, Tembe N, et al. Optimizing the immunogenicity of HIV prime-boost DNA-MVA-rgp140\/GLA vaccines in a phase II randomized factorial trial design. PLoS ONE. 2018;13(11): e0206838.","journal-title":"PLoS ONE"},{"issue":"5","key":"4459_CR83","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1056\/NEJMoa1110711","volume":"367","author":"MC Thigpen","year":"2012","unstructured":"Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367(5):423\u201334.","journal-title":"N Engl J Med"},{"issue":"5","key":"4459_CR84","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1007\/s10461-014-0891-z","volume":"19","author":"PM Kebaabetswe","year":"2015","unstructured":"Kebaabetswe PM, Stirratt MJ, McLellan-Lemal E, Henderson FL, Gray SC, Rose CE, et al. Factors associated with adherence and concordance between measurement strategies in an HIV daily oral Tenofovir\/Emtricitibine as pre-exposure prophylaxis (prep) clinical trial, Botswana, 2007\u20132010. AIDS Behav. 2015;19(5):758\u201369.","journal-title":"AIDS Behav"},{"issue":"5","key":"4459_CR85","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1097\/QAI.0000000000001143","volume":"73","author":"DA Gust","year":"2016","unstructured":"Gust DA, Soud F, Hardnett FP, Malotte CK, Rose C, Kebaabetswe P, et al. Evaluation of sexual risk behavior among study participants in the TDF2 PrEP study among heterosexual adults in Botswana. J Acquir Immune Defic Syndr. 2016;73(5):556\u201363.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"3","key":"4459_CR86","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0147743","volume":"11","author":"A Nel","year":"2016","unstructured":"Nel A, Bekker LG, Bukusi E, Hellstr\u04e7m E, Kotze P, Louw C, et al. Safety, acceptability and adherence of Dapivirine vaginal ring in a microbicide clinical trial conducted in multiple countries in Sub-Saharan Africa. PLoS ONE. 2016;11(3): e0147743.","journal-title":"PLoS ONE"},{"issue":"22","key":"4459_CR87","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1056\/NEJMoa1602046","volume":"375","author":"A Nel","year":"2016","unstructured":"Nel A, van Niekerk N, Kapiga S, Bekker LG, Gama C, Gill K, et al. Safety and efficacy of a Dapivirine vaginal ring for HIV prevention in women. N Engl J Med. 2016;375(22):2133\u201343.","journal-title":"N Engl J Med"},{"issue":"9","key":"4459_CR88","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0012873","volume":"5","author":"W Jaoko","year":"2010","unstructured":"Jaoko W, Karita E, Kayitenkore K, Omosa-Manyonyi G, Allen S, Than S, et al. Safety and immunogenicity study of Multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa. PLoS ONE. 2010;5(9): e12873.","journal-title":"PLoS ONE"},{"issue":"3","key":"4459_CR89","doi-asserted-by":"publisher","first-page":"714","DOI":"10.4161\/hv.27559","volume":"10","author":"C Schmidt","year":"2014","unstructured":"Schmidt C, Jaoko W, Omosa-Manyonyi G, Kaleebu P, Mpendo J, Nanvubya A, et al. Long-term follow-up of study participants from prophylactic HIV vaccine clinical trials in Africa. Hum Vaccin Immunother. 2014;10(3):714\u201323.","journal-title":"Hum Vaccin Immunother"},{"issue":"8","key":"4459_CR90","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25571","volume":"23","author":"BH Chi","year":"2020","unstructured":"Chi BH, Mbori-Ngacha D, Essajee S, Mofenson LM, Tsiouris F, Mahy M, et al. Accelerating progress towards the elimination of mother-to-child transmission of HIV: a narrative review. J Int AIDS Soc. 2020;23(8): e25571.","journal-title":"J Int AIDS Soc"},{"key":"4459_CR91","volume-title":"Ending the evidence gap for pregnant women around HIV & co-infections: A call to action","author":"The PHASES Working Group","year":"2020","unstructured":"The PHASES Working Group. Ending the evidence gap for pregnant women around HIV & co-infections: A call to action. Chapel Hill: PHASES; 2020."},{"key":"4459_CR92","volume-title":"Ethical considerations in HIV prevention trials: UNAIDS and WHO guidance document","author":"UNAIDS and WHO","year":"2021","unstructured":"UNAIDS and WHO. Ethical considerations in HIV prevention trials: UNAIDS and WHO guidance document. Geneva: UNAIDS and WHO; 2021."},{"issue":"12","key":"4459_CR93","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25846","volume":"24","author":"AD Lyerly","year":"2021","unstructured":"Lyerly AD, Beigi R, Bekker LG, Chi BH, Cohn SE, Diallo DD, et al. Ending the evidence gap for pregnancy, HIV and co-infections: ethics guidance from the PHASES project. J Int AIDS Soc. 2021;24(12): e25846.","journal-title":"J Int AIDS Soc"},{"issue":"5","key":"4459_CR94","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1056\/NEJMoa0707957","volume":"359","author":"L Van Damme","year":"2008","unstructured":"Van Damme L, Govinden R, Mirembe FM, Gu\u00e9dou F, Solomon S, Becker ML, et al. Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. N Engl J Med. 2008;359(5):463\u201372.","journal-title":"N Engl J Med"},{"issue":"7760","key":"4459_CR95","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/s41586-019-1200-9","volume":"570","author":"L Dwyer-Lindgren","year":"2019","unstructured":"Dwyer-Lindgren L, Cork MA, Sligar A, Steuben KM, Wilson KF, Provost NR, et al. Mapping HIV prevalence in sub-Saharan Africa between 2000 and 2017. Nature. 2019;570(7760):189\u201393.","journal-title":"Nature"},{"key":"4459_CR96","unstructured":"Sharan M, Ahmed S, May J, Soucat A. Family Planning Trends in Sub-Saharan Africa: Progress, Prospects, and Lessons Learned. Success Stories from A Dynamic Continent. 2011."},{"issue":"1","key":"4459_CR97","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12978-022-01332-x","volume":"19","author":"I Boadu","year":"2022","unstructured":"Boadu I. Coverage and determinants of modern contraceptive use in sub-Saharan Africa: further analysis of demographic and health surveys. Reprod Health. 2022;19(1):18.","journal-title":"Reprod Health"},{"issue":"1","key":"4459_CR98","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1186\/s13063-021-05792-7","volume":"22","author":"J Hanass-Hancock","year":"2021","unstructured":"Hanass-Hancock J, Carpenter B, Reddy T, Nzuza A, Gaffoor Z, Goga A, et al. Participants\u2019 characteristics and motivations to screen for HIV vaccine and monoclonal antibody trials in KwaZulu-Natal, South Africa. Trials. 2021;22(1):897.","journal-title":"Trials"},{"issue":"44","key":"4459_CR99","doi-asserted-by":"publisher","first-page":"5055","DOI":"10.1016\/j.vaccine.2013.08.080","volume":"31","author":"G Asiki","year":"2013","unstructured":"Asiki G, Abaasa A, Ruzagira E, Kibengo F, Bahemuka U, Mulondo J, et al. Willingness to participate in HIV vaccine efficacy trials among high risk men and women from fishing communities along Lake Victoria in Uganda. Vaccine. 2013;31(44):5055\u201361.","journal-title":"Vaccine"},{"issue":"1","key":"4459_CR100","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12905-019-0713-6","volume":"19","author":"AWK Katz","year":"2019","unstructured":"Katz AWK, Mensch BS, Woeber K, Musara P, Etima J, van der Straten A. Understanding women\u2019s motivations to participate in MTN-003\/VOICE, a phase 2b HIV prevention trial with low adherence. BMC Womens Health. 2019;19(1):18.","journal-title":"BMC Womens Health"},{"issue":"9","key":"4459_CR101","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0183788","volume":"12","author":"BA Nyaoke","year":"2017","unstructured":"Nyaoke BA, Mutua GN, Sajabi R, Nyasani D, Mureithi MW, Anzala OA. Volunteer motivators for participating in HIV vaccine clinical trials in Nairobi, Kenya. PLoS ONE. 2017;12(9): e0183788.","journal-title":"PLoS ONE"},{"key":"4459_CR102","unstructured":"Magical thinking? FEM-PrEP tiral may have failed because participatns used testing as prevention [press release]. aidsmap2013."},{"key":"4459_CR103","doi-asserted-by":"publisher","DOI":"10.3389\/frph.2021.639391","volume":"3","author":"K Closson","year":"2021","unstructured":"Closson K, Lee L, Dietrich JJ, Beksinska ME, Hornschuh S, Smith P, et al. Gender and Power Dynamics of Social Relationships Shape Willingness to Participate in Biomedical HIV Prevention Research Among South African Adolescents and Young Adults. Frontiers in reproductive health. 2021;3: 639391.","journal-title":"Frontiers in reproductive health"},{"key":"4459_CR104","unstructured":"World Bank. World Databank: Fertility rate, total (births per woman) - Sub-Saharan Africa 2023 [Available from: https:\/\/data.worldbank.org\/indicator\/SP.DYN.TFRT.IN?locations=ZG."},{"issue":"1","key":"4459_CR105","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1186\/s12905-022-01920-w","volume":"22","author":"AB Teshale","year":"2022","unstructured":"Teshale AB, Worku MG, Tesema GA. Fertility decision and its associated factors in Sub-Saharan Africa: a multilevel multinomial logistic regression analysis. BMC Womens Health. 2022;22(1):337.","journal-title":"BMC Womens Health"},{"issue":"1","key":"4459_CR106","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1186\/s12884-020-03470-1","volume":"20","author":"BO Ahinkorah","year":"2020","unstructured":"Ahinkorah BO, Seidu AA, Armah-Ansah EK, Budu E, Ameyaw EK, Agbaglo E, et al. Drivers of desire for more children among childbearing women in sub-Saharan Africa: implications for fertility control. BMC Pregnancy Childbirth. 2020;20(1):778.","journal-title":"BMC Pregnancy Childbirth"},{"key":"4459_CR107","unstructured":"Interagency Gender Working Group. Gender Integration Continuum: Gender Equality Continuum Tool. USAID; 2013."},{"issue":"1","key":"4459_CR108","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1097\/QAI.0b013e31813e5fa5","volume":"46","author":"KM Macqueen","year":"2007","unstructured":"Macqueen KM, Johnson L, Alleman P, Akumatey B, Lawoyin T, Nyiama T. Pregnancy prevention practices among women with multiple partners in an HIV prevention trial. J Acquir Immune Defic Syndr. 2007;46(1):32\u20138.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"3","key":"4459_CR109","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.contraception.2019.06.006","volume":"100","author":"CA Chappell","year":"2019","unstructured":"Chappell CA, Harkoo I, Szydlo DW, Bunge KE, Singh D, Nakabiito C, et al. Contraceptive method switching among women living in sub-Saharan Africa participating in an HIV-1 prevention trial: a prospective cohort study. Contraception. 2019;100(3):214\u20138.","journal-title":"Contraception"},{"issue":"1","key":"4459_CR110","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s12905-021-01321-5","volume":"21","author":"J Leslie","year":"2021","unstructured":"Leslie J, Kiweewa F, Palanee-Phillips T, Bunge K, Mhlanga F, Kamira B, et al. Experiences with simultaneous use of contraception and the vaginal ring for HIV prevention in sub-Saharan Africa. BMC Womens Health. 2021;21(1):175.","journal-title":"BMC Womens Health"},{"key":"4459_CR111","doi-asserted-by":"crossref","DOI":"10.56759\/rgxl7405","volume-title":"International ethical guidelines for health-related research involving humans","author":"Council for International Organizations of Medical Sciences","year":"2016","unstructured":"Council for International Organizations of Medical Sciences. International ethical guidelines for health-related research involving humans. 4th ed. Geneva: CIOMS; 2016.","edition":"4"},{"key":"4459_CR112","unstructured":"AVAC\/PHASES. Advancing HIV Prevention Research in Pregnancy and Lactating People (PLP): Think Tank Report & Action Plan. New York: AVAC; 2023."},{"key":"4459_CR113","volume-title":"Research for informed choices: Accelerating the study of new drugs for HIV in pregnant and breastfeeding women","author":"World Health Organization","year":"2021","unstructured":"World Health Organization. Research for informed choices: Accelerating the study of new drugs for HIV in pregnant and breastfeeding women. A Call to Action. Geneva: World Health Organization; 2021."},{"issue":"6651","key":"4459_CR114","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1126\/science.adh3104","volume":"380","author":"J Sugarman","year":"2023","unstructured":"Sugarman J, Wenner DM, Rid A, Meltzer Henry L, Luna F, Klitzman R, et al. Ethical research when abortion access is legally restricted. Science. 2023;380(6651):1224\u20136.","journal-title":"Science"},{"issue":"4","key":"4459_CR115","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0215052","volume":"14","author":"RCM van Aert","year":"2019","unstructured":"van Aert RCM, Wicherts JM, van Assen M. Publication bias examined in meta-analyses from psychology and medicine: A meta-meta-analysis. PLoS ONE. 2019;14(4): e0215052.","journal-title":"PLoS ONE"},{"issue":"7304","key":"4459_CR116","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1136\/bmj.323.7304.101","volume":"323","author":"JA Sterne","year":"2001","unstructured":"Sterne JA, Egger M, Smith GD. Systematic reviews in health care: Investigating and dealing with publication and other biases in meta-analysis. BMJ (Clinical research ed). 2001;323(7304):101\u20135.","journal-title":"BMJ (Clinical research ed)"}],"container-title":["AIDS and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10461-024-04459-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10461-024-04459-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10461-024-04459-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T13:14:57Z","timestamp":1728911697000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10461-024-04459-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,17]]},"references-count":116,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["4459"],"URL":"https:\/\/doi.org\/10.1007\/s10461-024-04459-z","relation":{},"ISSN":["1090-7165","1573-3254"],"issn-type":[{"value":"1090-7165","type":"print"},{"value":"1573-3254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,17]]},"assertion":[{"value":"26 July 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no competing interests to declare that are relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interest"}},{"value":"This study is a systematic review and meta-analysis, not human subjects research. FHI 360\u2019s Office of International Research Ethics (1918056) confirmed that no ethical approval is required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"As this meta-analysis was not considered human subjects research and did not involve data collection with human subjects, consent to participate does not apply.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"As this meta-analysis was not considered human subjects research and did not involve data collection with human subjects, consent to publish does not apply.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Publications"}}]}}